Angelo Corti researcher
Corti, Angelo.
Corti, Angelo 19..-.... médecin
VIAF ID: 167043780 (Personal)
Permalink: http://viaf.org/viaf/167043780
Preferred Forms
- 100 0 _ ‡a Angelo Corti ‡c researcher
- 200 _ | ‡a Corti ‡b Angelo ‡f 19..-.... ‡c médecin
- 100 1 _ ‡a Corti, Angelo
-
-
-
-
- 100 1 _ ‡a Corti, Angelo ‡d 19..-... ‡c médecin
-
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Ernani : opera in four acts | |
Idiotope determining regions of a mouse monoclonal antibody and its humanized versions | |
Immunogenic and structural properties of the Asn-Gly-Arg | |
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. | |
Improving drug penetration to curb tumor drug resistance. | |
Increased low-grade inflammation is associated with lack of functional response to carvedilol in patients with systolic heart failure | |
Influence of vasostatins, the chromogranin A-derived peptides, on the working heart of the eel (Anguilla anguilla): negative inotropy and mechanism of action | |
Inhibition of chronic lymphocytic leukemia progression by full-length chromogranin A and its N-terminal fragment in mouse models | |
Interactions of chromogranin A-derived vasostatins and monolayers of phosphatidylserine, phosphatidylcholine and phosphatidylethanolamine | |
Inverse polymerase chain reaction for cloning complete human immunoglobulin variable regions and leaders conserving the original sequence. | |
Isoaspartate-dependent molecular switches for integrin-ligand recognition | |
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif | |
Kinetic analysis of TNF-alpha oligomer-monomer transition by surface plasmon resonance and immunochemical methods. | |
Liposome-mediated therapy of neuroblastoma | |
Long human CHGA flanking chromosome 14 sequence required for optimal BAC transgenic "rescue" of disease phenotypes in the mouse Chga knockout | |
MachineWorld : introduction à la technique des machines | |
Mode of interaction between a monoclonal antibody and human TNFα | |
Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor | |
Muscle injury, impaired muscle function and insulin resistance in Chromogranin A-knockout mice. | |
Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function. | |
The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration. | |
The neovasculature homing motif NGR: more than meets the eye. | |
Neuroendocrine Modulation Induced by Selective Blockade of TNF- in Rheumatoid Arthritis | |
NF-kappa B-mediated regulation of urokinase gene expression by PMA and TNF-alpha in human A549 cells | |
NGR-tagged nano-gold: A new CD13-selective carrier for cytokine delivery to tumors | |
Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. | |
Oral direct thrombin inhibition: a double-edged sword? | |
Overexpression of the hereditary hemochromatosis protein, HFE, in HeLa cells induces an iron-deficient phenotype | |
Oxidation-induced structural changes of ceruloplasmin foster NGR motif deamidation that promotes integrin binding and signaling | |
Oxidative stress biomarkers and chromogranin A in uremic patients: Effects of dialytic treatment | |
PCR amplification of antibody variable regions using primers that anneal to constant regions. | |
Peptide microarrays for the characterization of antigenic regions of human chromogranin A. | |
pGlu-serpinin protects the normotensive and hypertensive heart from ischemic injury | |
Plasma Chromogranin A as a marker of cardiovascular involvement in Erdheim-Chester disease | |
Plasma levels of vasostatin-1, a chromogranin A fragment, are associated with carotid artery maximum stenosis: A pilot study. | |
Post cardiac surgery diaphragmatic spasm successfully treated with gabapentin | |
Processing of chromogranins/secretogranin in patients with diabetic retinopathy | |
Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells | |
Production and Structure Characterization of Recombinant Chromogranin A N-Terminal Fragments (Vasostatins). Evidence of Dimmer-Monomer Equilibria | |
Pushing tumor cells towards a malignant phenotype: stimuli from the microenvironment, intercellular communications and alternative roads | |
Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart | |
Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. | |
Selective imaging of the angiogenic relevant integrins α5β1 and αvβ3. | |
Selenoprotein T as a novel cardiac modulator : from production to expression measurement and pathophysiological implications. | |
Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors | |
sp. | |
Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement | |
Spontaneous formation of L-isoaspartate and gain of function in fibronectin. | |
A stapled chromogranin A-derived peptide is a potent dual ligand for integrins αvβ6 and αvβ8 | |
Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin | |
Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells | |
Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif | |
Synthesis and characterization of D-Alanyl-D-Alanine-Agarose | |
T Cells Redirected to a Minor Histocompatibility Antigen Instruct Intratumoral TNFα Expression and Empower Adoptive Cell Therapy for Solid Tumors. | |
Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms | |
Targeted drug delivery and penetration into solid tumors | |
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy | |
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression | |
Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy | |
TNF-α in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. | |
Tumor cell-associated immune checkpoint molecules - Drivers of malignancy and stemness. | |
Tumor Necrosis Factor | |
Tumor vasculature targeting through NGR peptide-based drug delivery systems | |
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer | |
Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms. | |
Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance | |
The vasostatin-I fragment of chromogranin A inhibits VEGF-induced endothelial cell proliferation and migration | |
Won't you come on in? How to favor lymphocyte infiltration in tumors |